The biology of Theileria parva and control of East Coast fever - Current status and future trends

详细信息    查看全文

• 作者：Vishvanath Nene^a ; ^b ; ^{v.nene@cgiar.org" class="auth_mail" title="E-mail the corresponding author} ; Henry Kiara^a ; Anna Lacasta^a ; Roger Pelle^a ; Nicholas Svitek^a ; Lucilla Steinaa^a
• 关键词：BoLA ; bovine leukocyte antigen ; CD ; cluster of differentiation ; cM ; centiMorgan ; ELISA ; enzyme-linked immunosorbent assay ; ELISpot ; enzyme-linked immunospot assay ; IFN-γ ; interferon-γ ; ITM ; infection and treatment method ; mAb ; monoclonal antibody ; MHC ; major histocompatibility complex ; VNTR ; variable number of tandem repeat
• 刊名：Ticks and Tick-borne Diseases
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：7
• 期：4
• 页码：549-564
• 全文大小：2682 K

文摘

Tremendous progress has been made over the last ten years on East Coast fever (ECF) research. Publication of a reference genome sequence of Theileria parva, the causative agent of ECF, has led to a more thorough characterization of the genotypic and antigenic diversity of the pathogen. It also facilitated identification of antigens that are targets of bovine major histocompatibility complex class I restricted cytotoxic T-lymphocytes (CTLs), induced by a live parasite-based infection and treatment method (ITM) vaccine. This has led to improved knowledge of epitope-specific T-cell responses to ITM that most likely contribute to the phenomenon of strain-specific immunity. The Muguga cocktail ITM vaccine, which provides broad-spectrum immunity to ECF is now a registered product in three countries in eastern Africa. Effort is directed at improving and scaling up the production process to make this vaccine more widely available on a commercial basis in the region. Meanwhile, research to develop a subunit vaccine based on parasite neutralizing antibodies and CTLs has been revived through convening of a research consortium to develop proof-of-concept for a next generation vaccine. Many new scientific and technical advances are facilitating this objective. Hence, the next decade promises even more progress toward an improved control of ECF.